Atara Biotherapeutics (ATRA) Depreciation & Amortization (CF) (2013 - 2026)

Atara Biotherapeutics has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $29000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 98.38% year-over-year to $29000.0; the trailing twelve-month figure through Mar 2026 stood at $350000.0 (down 93.58% YoY), and the FY2025 full-year result was $2.1 million, down 58.11% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $29000.0, down from $49000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.8 million in Q1 2025, with the low at $29000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $1.0 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) advanced 29.04% — and 2026, when it tumbled 98.38%.
• Atara Biotherapeutics' Depreciation & Amortization (CF) stood at $1.3 million in 2022, then declined by 3.98% to $1.2 million in 2023, then dropped by 8.71% to $1.1 million in 2024, then sank by 95.55% to $49000.0 in 2025, then sank by 40.82% to $29000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $29000.0 (Q1 2026), $49000.0 (Q4 2025), and $36000.0 (Q3 2025), per Business Quant data.